Harvard Bioscience Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.11
- Today's High:
- $4.27
- Open Price:
- $4.17
- 52W Low:
- $1.98
- 52W High:
- $6.29
- Prev. Close:
- $4.16
- Volume:
- 63264
Company Statistics
- Market Cap.:
- $177.58 million
- Book Value:
- 1.766
- Revenue TTM:
- $114.08 million
- Operating Margin TTM:
- -0.21%
- Gross Profit TTM:
- $62.29 million
- Profit Margin:
- -4.76%
- Return on Assets TTM:
- -0.1%
- Return on Equity TTM:
- -7.1%
Company Profile
Harvard Bioscience Inc had its IPO on 2000-12-07 under the ticker symbol HBIO.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Harvard Bioscience Inc has a staff strength of 436 employees.
Stock update
Shares of Harvard Bioscience Inc opened at $4.17 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.11 - $4.27, and closed at $4.21.
This is a +1.2% increase from the previous day's closing price.
A total volume of 63,264 shares were traded at the close of the day’s session.
In the last one week, shares of Harvard Bioscience Inc have slipped by -4.54%.
Harvard Bioscience Inc's Key Ratios
Harvard Bioscience Inc has a market cap of $177.58 million, indicating a price to book ratio of 1.5973 and a price to sales ratio of 0.8475.
In the last 12-months Harvard Bioscience Inc’s revenue was $114.08 million with a gross profit of $62.29 million and an EBITDA of $7.10 million. The EBITDA ratio measures Harvard Bioscience Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Harvard Bioscience Inc’s operating margin was -0.21% while its return on assets stood at -0.1% with a return of equity of -7.1%.
In Q2, Harvard Bioscience Inc’s quarterly earnings growth was a negative -80.3% while revenue growth was a negative 1.5%.
Harvard Bioscience Inc’s PE and PEG Ratio
- Forward PE
- 14.9254
- Trailing PE
- 0
- PEG
- 2.89
Its diluted EPS in the last 12-months stands at $-0.12 per share while it has a forward price to earnings multiple of 14.9254 and a PEG multiple of 2.89. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Harvard Bioscience Inc’s profitability.
Harvard Bioscience Inc stock is trading at a EV to sales ratio of 1.4135 and a EV to EBITDA ratio of 69.2751. Its price to sales ratio in the trailing 12-months stood at 0.8475.
Harvard Bioscience Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $142.90 million
- Total Liabilities
- $22.94 million
- Operating Cash Flow
- $-625000.00
- Capital Expenditure
- $625000
- Dividend Payout Ratio
- 0%
Harvard Bioscience Inc ended 2024 with $142.90 million in total assets and $0 in total liabilities. Its intangible assets were valued at $142.90 million while shareholder equity stood at $75.39 million.
Harvard Bioscience Inc ended 2024 with $667000.00 in deferred long-term liabilities, $22.94 million in other current liabilities, 457000.00 in common stock, $-142548000.00 in retained earnings and $56.77 million in goodwill. Its cash balance stood at $4.32 million and cash and short-term investments were $4.32 million. The company’s total short-term debt was $3,220,000 while long-term debt stood at $38.20 million.
Harvard Bioscience Inc’s total current assets stands at $52.62 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $16.90 million compared to accounts payable of $4.72 million and inventory worth $26.09 million.
In 2024, Harvard Bioscience Inc's operating cash flow was $-625000.00 while its capital expenditure stood at $625000.
Comparatively, Harvard Bioscience Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.21
- 52-Week High
- $6.29
- 52-Week Low
- $1.98
- Analyst Target Price
- $6.92
Harvard Bioscience Inc stock is currently trading at $4.21 per share. It touched a 52-week high of $6.29 and a 52-week low of $6.29. Analysts tracking the stock have a 12-month average target price of $6.92.
Its 50-day moving average was $4.72 and 200-day moving average was $4.13 The short ratio stood at 5.43 indicating a short percent outstanding of 0%.
Around 696.5% of the company’s stock are held by insiders while 7658.6% are held by institutions.
Frequently Asked Questions About Harvard Bioscience Inc
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. The company was founded in 1901 and is based in Holliston, Massachusetts.